Covered recipient · General Payments record
JULIO C CHAVEZ
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$60,194.18
52 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $30,384.50 | 10 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,425.00 | 11 |
| Travel and Lodging | $4,202.76 | 9 |
| Food and Beverage | $1,181.92 | 22 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $25,162.05 | 14 |
| Gilead Sciences, Inc. | $15,102.50 | 9 |
| E.R. Squibb & Sons, L.L.C. | $7,562.00 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $3,005.96 | 4 |
| Genmab U.S., Inc. | $2,825.07 | 6 |
| Kite Pharma, Inc. | $2,354.89 | 6 |
| ADC Therapeutics America, Inc. | $1,844.81 | 2 |
| AbbVie Inc. | $1,837.50 | 2 |
| Celgene Corporation | $262.61 | 2 |
| Janssen Biotech, Inc. | $135.76 | 1 |
| Ipsen Biopharmaceuticals, Inc | $59.32 | 1 |
| Genentech USA, Inc. | $41.71 | 1 |
Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JULIO C CHAVEZ
NPI 1750543948 · CMS profile ID 1011346
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1750543948?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JULIO C CHAVEZ, NPI 1750543948, CMS profile ID 1011346. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750543948?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JULIO C CHAVEZ, NPI 1750543948, CMS profile ID 1011346. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750543948?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JULIO C CHAVEZ, NPI 1750543948, CMS profile ID 1011346, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1750543948?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
52 matching records · $60,194.18 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–52 of 52.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,372.00 | 01/12/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015546587 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,384.00 | 01/12/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015546591 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $9,911.43 | 6 |
| PY2025 | Principal investigator | $2,746,782.29 | 130 |
| PY2024 | Recipient | $2,408.08 | 7 |
| PY2024 | Principal investigator | $2,404,588.27 | 146 |
| PY2023 | Recipient | $8,104.48 | 3 |
| PY2023 | Principal investigator | $1,978,343.29 | 113 |
| PY2022 | Recipient | $3,786.08 | 1 |
| PY2022 | Principal investigator | $1,876,549.98 | 128 |
| PY2021 | Recipient | $370.58 | 2 |
| PY2021 | Principal investigator | $1,834,517.85 | 196 |
| PY2020 | Recipient | $2,475.00 | 1 |
| PY2020 | Principal investigator | $2,938,832.81 | 108 |
| PY2019 | Recipient | $1,469.41 | 7 |
| PY2019 | Principal investigator | $2,239,215.60 | 65 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
136 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Hoffmann-La Roche Limited | $84,188.94 | 12/24/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550391 |
| Principal investigator 1 | Genentech, Inc. | $258.00 | 12/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550591 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $39,644.00 | 12/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550395 |
| Recipient | F. Hoffmann-La Roche AG | $1,051.67 | 12/12/2025 | Covered Recipient Physician | Baseline characteristics and outcomes for large B-cell lymphoma (LBCL) patients previously treated with gemcitabine-oxaliplatin plus rituximab (R-GemOx) and subsequently enrolled in clinical trials GO40516 or GO29781 in the United States (US) | No dispute reported | 06/30/2026 | 1211536961 |
| Recipient | F. Hoffmann-La Roche AG | $616.07 | 12/12/2025 | Covered Recipient Physician | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211536964 |
| Principal investigator 1 | BeOne Medicines Ltd. | $67,072.00 | 12/10/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190337657 |
| Principal investigator 1 | Epizyme, Inc. | $83.33 | 12/10/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282235 |
| Principal investigator 1 | Epizyme, Inc. | $85.84 | 12/10/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282237 |
| Principal investigator 1 | Epizyme, Inc. | $258.00 | 12/10/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282239 |
| Principal investigator 1 | Epizyme, Inc. | $774.00 | 12/10/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282243 |
| Principal investigator 1 | Epizyme, Inc. | $1,500.00 | 12/10/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282247 |
| Principal investigator 1 | Epizyme, Inc. | $1,536.00 | 12/10/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282249 |
| Principal investigator 1 | Epizyme, Inc. | $2,627.00 | 12/10/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282251 |
| Recipient | F. Hoffmann-La Roche AG | $460.12 | 12/10/2025 | Covered Recipient Physician | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211536972 |
| Principal investigator 1 | Genentech, Inc. | $258.00 | 12/10/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550593 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 12/10/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550597 |
| Recipient | F. Hoffmann-La Roche AG | $440.24 | 12/08/2025 | Covered Recipient Physician | Baseline characteristics and outcomes for large B-cell lymphoma (LBCL) patients previously treated with gemcitabine-oxaliplatin plus rituximab (R-GemOx) and subsequently enrolled in clinical trials GO40516 or GO29781 in the United States (US) | No dispute reported | 06/30/2026 | 1211536968 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $135,594.72 | 12/01/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550387 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $32,850.80 | 11/14/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550382 |
| Principal investigator 1 | BeOne Medicines Ltd. | $67,072.00 | 11/10/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190330649 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $24,347.88 | 11/07/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Anti-Lymphoma Agents in Subjects with Relapsed OR Refractory non-Hodgkin Lymphomas (R/R NHL). | No dispute reported | 06/30/2026 | 1236000586 |
| Principal investigator 1 | BeOne Medicines Ltd. | $8,384.00 | 11/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190337659 |
| Principal investigator 1 | BeOne Medicines Ltd. | $25,152.00 | 11/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190337663 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 11/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550577 |
| Principal investigator 1 | Genentech, Inc. | $4,848.00 | 11/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550581 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 11/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550584 |
| Principal investigator 1 | Genentech, Inc. | $1,391.00 | 11/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550587 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $678.00 | 11/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550374 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $13,923.00 | 11/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550378 |
| Principal investigator 1 | Epizyme, Inc. | $916.63 | 10/31/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282245 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $12,654.54 | 10/28/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333141 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $98,867.14 | 10/15/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550355 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $99,030.34 | 10/15/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550359 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $21,587.56 | 10/15/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550366 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $816.00 | 10/15/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550370 |
| Principal investigator 1 | Genmab U.S., Inc. | $420.00 | 10/14/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235930250 |
| Principal investigator 1 | Genmab U.S., Inc. | $402.90 | 10/14/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235930264 |
| Principal investigator 1 | Epizyme, Inc. | $429.20 | 10/10/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282241 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,424.00 | 10/09/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235930247 |
| Recipient | Novartis Pharmaceuticals Corporation | $115.00 | 10/09/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291872 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $266.00 | 10/08/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550348 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $266.00 | 10/08/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550362 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $32,501.81 | 10/07/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333137 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,060.00 | 10/01/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550350 |
| Principal investigator 1 | Genmab U.S., Inc. | $130.56 | 09/18/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925948 |
| Principal investigator 1 | Genentech, Inc. | $1,071.00 | 09/11/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550561 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,005.00 | 09/02/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma | No dispute reported | 06/30/2026 | 1190301189 |
| Principal investigator 1 | Epizyme, Inc. | $1,001.00 | 08/28/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282867 |
| Principal investigator 1 | Celgene Corporation | $104,895.82 | 08/27/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222305376 |
| Principal investigator 1 | Genmab U.S., Inc. | $7,686.72 | 08/27/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925960 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $21,021.00 | 08/27/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550334 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $707.00 | 08/27/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550337 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $140,587.41 | 08/26/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333134 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,169.76 | 08/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925945 |
| Principal investigator 1 | Genmab U.S., Inc. | $119,090.10 | 08/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925956 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $111,403.20 | 08/14/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL | No dispute reported | 06/30/2026 | 1190309562 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $369.00 | 08/12/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190332349 |
| Principal investigator 1 | Genentech, Inc. | $136.00 | 08/01/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550565 |
| Principal investigator 1 | Genentech, Inc. | $258.00 | 08/01/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550568 |
| Principal investigator 1 | Genentech, Inc. | $516.00 | 08/01/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550572 |
| Principal investigator 1 | Epizyme, Inc. | $958.80 | 07/30/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282865 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $266.00 | 07/30/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550344 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $460.00 | 07/29/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190332343 |
| Principal investigator 1 | Genmab U.S., Inc. | $266.00 | 07/29/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925941 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $421.62 | 07/28/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL | No dispute reported | 06/30/2026 | 1190301203 |
| Principal investigator 1 | Genmab U.S., Inc. | $19,216.80 | 07/25/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925952 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,000.00 | 07/22/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190332339 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,762.00 | 07/22/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190332341 |
| Principal investigator 1 | BeOne Medicines Ltd. | $67,072.00 | 07/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190337749 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $29,785.21 | 07/15/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333129 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $11,072.00 | 07/07/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190332345 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $369.00 | 07/07/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190332347 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,000.00 | 07/02/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550341 |
| Principal investigator 1 | Genmab U.S., Inc. | $64,340.24 | 06/24/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925916 |
| Principal investigator 1 | Epizyme, Inc. | $258.00 | 06/23/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282863 |
| Principal investigator 1 | Genentech, Inc. | $258.00 | 06/18/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550510 |
| Principal investigator 1 | Genentech, Inc. | $136.00 | 06/18/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550514 |
| Principal investigator 1 | Genentech, Inc. | $516.00 | 06/18/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550525 |
| Principal investigator 1 | Genentech, Inc. | $516.00 | 06/18/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550549 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $13,678.74 | 06/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190326716 |
| Principal investigator 1 | Genentech, Inc. | $136.00 | 06/13/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550534 |
| Principal investigator 1 | Genmab U.S., Inc. | $321,923.06 | 06/13/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925933 |
| Principal investigator 1 | BeOne Medicines Ltd. | $67,072.00 | 06/11/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190342701 |
| Principal investigator 1 | Genmab U.S., Inc. | $266.00 | 06/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925924 |
| Principal investigator 1 | Genentech, Inc. | $774.00 | 06/04/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550506 |
| Principal investigator 1 | Genentech, Inc. | $516.00 | 06/04/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550528 |
| Principal investigator 1 | Genentech, Inc. | $258.00 | 06/04/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550542 |
| Principal investigator 1 | Genentech, Inc. | $258.00 | 06/04/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550553 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $20,799.42 | 05/30/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190326718 |
| Principal investigator 1 | Genmab U.S., Inc. | $204.00 | 05/28/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925912 |
| Principal investigator 1 | Genentech, Inc. | $516.00 | 05/23/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550502 |
| Principal investigator 1 | Genentech, Inc. | $516.00 | 05/23/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550517 |
| Principal investigator 1 | Genentech, Inc. | $1,032.00 | 05/23/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550521 |
| Principal investigator 1 | Genentech, Inc. | $516.00 | 05/23/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550538 |
| Principal investigator 1 | Genentech, Inc. | $516.00 | 05/23/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550545 |
| Principal investigator 1 | Genmab U.S., Inc. | $266.00 | 05/22/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925905 |
| Principal investigator 1 | Celgene Corporation | $71,268.76 | 05/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222305336 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,865.00 | 05/14/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550330 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $73,461.00 | 05/12/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190326720 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,603.50 | 05/09/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma | No dispute reported | 06/30/2026 | 1190296547 |
| Principal investigator 1 | Genmab U.S., Inc. | $420.00 | 05/08/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925909 |
| Principal investigator 1 | Genmab U.S., Inc. | $25,943.36 | 05/08/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925920 |
| Principal investigator 1 | Celgene Corporation | $42,184.00 | 05/02/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222304583 |
| Principal investigator 1 | Genmab U.S., Inc. | $204.00 | 04/24/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925937 |
| Principal investigator 1 | BeiGene, Ltd. | $75,456.00 | 04/09/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190324096 |
| Principal investigator 1 | Genentech, Inc. | $4,540.77 | 04/09/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550557 |
| Principal investigator 1 | BeiGene, Ltd. | $25,152.00 | 04/07/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190325464 |
| Principal investigator 1 | Genmab U.S., Inc. | $266.00 | 04/04/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925929 |
| Principal investigator 1 | Genentech, Inc. | $24,301.15 | 03/26/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | No dispute reported | 06/30/2026 | 1211550498 |
| Principal investigator 1 | Genmab U.S., Inc. | $266.00 | 03/13/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925895 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $44,039.00 | 03/12/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase 1b study of each glofitammab and mosunetuzumab in combination with M CC20 and M CC82 in NHL | No dispute reported | 06/30/2026 | 1211550325 |
| Principal investigator 1 | Kite Pharma, Inc. | $4,950.00 | 03/11/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067528 |
| Principal investigator 1 | Kite Pharma, Inc. | $8,190.00 | 03/11/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067531 |
| Principal investigator 1 | Epizyme, Inc. | $258.00 | 03/04/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282861 |
| Principal investigator 1 | Genmab U.S., Inc. | $204.00 | 02/27/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925888 |
| Principal investigator 1 | Epizyme, Inc. | $1,400.80 | 02/13/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282859 |
| Principal investigator 1 | Genmab U.S., Inc. | $266.00 | 02/13/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925882 |
| Principal investigator 1 | Genmab U.S., Inc. | $382.16 | 02/13/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925885 |
| Principal investigator 1 | Kite Pharma, Inc. | $995.00 | 02/11/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067515 |
| Principal investigator 1 | Kite Pharma, Inc. | $250.00 | 02/11/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067521 |
| Principal investigator 1 | Genmab U.S., Inc. | $204.00 | 02/06/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925891 |
| Principal investigator 1 | Genmab U.S., Inc. | $14,727.10 | 02/06/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925902 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $371,425.00 | 02/04/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL | No dispute reported | 06/30/2026 | 1190295735 |
| Principal investigator 1 | Epizyme, Inc. | $431.00 | 01/29/2025 | Non-covered Recipient Entity Moffitt Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282857 |
| Principal investigator 1 | Kite Pharma, Inc. | $250.00 | 01/28/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067508 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,255.24 | 01/27/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL | No dispute reported | 06/30/2026 | 1190306227 |
| Principal investigator 1 | Kite Pharma, Inc. | $867.68 | 01/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067480 |
| Principal investigator 1 | Kite Pharma, Inc. | $0.20 | 01/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067487 |
| Principal investigator 1 | Kite Pharma, Inc. | $0.40 | 01/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067493 |
| Principal investigator 1 | Kite Pharma, Inc. | $204.00 | 01/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067502 |
| Principal investigator 1 | Genmab U.S., Inc. | $207.06 | 01/16/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | No dispute reported | 06/30/2026 | 1235925898 |
| Recipient | Novartis Pharmaceuticals Corporation | $7,228.33 | 01/15/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190293666 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $96.02 | 01/15/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma | No dispute reported | 06/30/2026 | 1190306221 |
| Principal investigator 1 | Kite Pharma, Inc. | $250.00 | 01/14/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067461 |
| Principal investigator 1 | Kite Pharma, Inc. | $250.00 | 01/14/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067467 |
| Principal investigator 1 | Kite Pharma, Inc. | $475.00 | 01/14/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212067474 |